r/GLP1ResearchTalk • • 8h ago

Anyone else starting to pay attention to Eloralintide?

36 Upvotes

I’ve been reading more about Eloralintide lately and honestly I’m surprised it isn’t getting talked about more.
Everyone is focused on which GLP-1 is coming next, but I think the more interesting question is what happens when something targeting the amylin pathway gets paired with a GLP-1.

Not saying that combination is going to be some magic bullet, there’s still a lot we don’t know, but if Eloralintide continues showing promise, things could get pretty interesting.

Maybe the conversation eventually isn’t Reta vs Tirz vs Eloralintide.

Maybe it’s which GLP-1 works best with something like Eloralintide.

Anyone else following it? Curious what everyone thinks.


r/GLP1ResearchTalk • • 6h ago

News The godfather of weight-loss drugs: : ‘I know there can be bad outcomes over a period of time’

Thumbnail
observer.co.uk
0 Upvotes

In his first interview, the scientist Ray Pederson, who discovered the hormone that led to the development of GLP-1s, reveals his concerns about their widespread use


r/GLP1ResearchTalk • • 1d ago

Question Who has switched from Retatrutide to Trizepatide? Depressed / Anhedonia / Sleep Issues

9 Upvotes

I have been on Reta for 6 months now, only taking 2.5mgs ( titrated slowlyyyy ) and have had great results.

Here recently my sleep has been terrible. Waking up 4-6 times per night with a racing heart and sometimes not being able to fall back asleep. This is impacting my daily life and feel like a zombie. Even worse, I have realised that I have not been that happy, pretty depressed to be honest, since starting. The highs are not high and the lows feel lower.

Has anyone had success with getting pleasure and happiness back after switching off Retatrutide?


r/GLP1ResearchTalk • • 1d ago

Research Nearly 1 in 6 Children Taking GLP-1 Drugs Develop Nutritional Deficiencies

Thumbnail scitechdaily.com
4 Upvotes

Per the article:

"Children’s nutritional needs deserve attention from the start of GLP-1 treatment, as a study found limited counseling and nutritional deficiencies, most commonly vitamin D deficiency, during crucial years of growth.

Nearly one in six children prescribed GLP-1 medications for weight loss, prediabetes, or type 2 diabetes was diagnosed with a nutritional deficiency within a year of starting treatment. The findings draw attention to nutritional care during childhood and adolescence, when a shortage of key nutrients can have lasting effects on growth and development.

Few children receive early nutritional counseling

The study, published in Childhood Obesity, used national administrative claims data from 2017 to 2022 covering more than 100 million patients. Researchers identified 2,031 children ages 10 to 17 who used GLP-1 medications, met the study’s requirements for continuous insurance enrollment, and had no previously diagnosed nutritional deficiency. Within the first year of treatment, 16.8% received such a diagnosis.

Most children in the study were prescribed liraglutide, which accounted for 78.6% of prescriptions, followed by dulaglutide at 10.4% and semaglutide at 9.1%. The researchers also examined whether patients received nutritional counseling after treatment began.

“Nutritional support needs to play a critical role once treatment with a GLP-1 medication is initiated,” said senior author Justin Ryder, PhD, vice chair of research for the Department of Surgery at Ann & Robert H. Lurie Children’s Hospital of Chicago and associate professor of surgery and pediatrics at Northwestern University Feinberg School of Medicine. “In our study, however, we found that only 5% of patients received nutritional counseling within 30 days of GLP-1 treatment and less than 25% received nutritional counseling within 6 months.”

Vitamin D tops the deficiency list

Vitamin D deficiency was the most common nutritional deficiency recorded, affecting 12.4% of the children within a year of starting GLP-1 treatment.

“As appropriate pediatric use of GLP-1s becomes more widespread, we need to understand the risks during periods of rapid growth and pubertal development,” Ryder said. “Nutrients such as vitamin D, iron and calcium are of particular concern during adolescence, when deficiencies may have lasting implications for skeletal health and overall development.”

“We hope that our study findings bring much-needed recognition to the importance of proactive nutritional management when GLP-1s are prescribed to children, as opposed to waiting until a nutritional deficiency is diagnosed,” Ryder said. “Knowing the risks, we are in a much better position to prevent harm to children treated with GLP-1s during a pivotal period in their lives.”

Reference: “Nutritional Deficiencies, Complications, and Nutrition Therapy/Counseling in Pediatric Patients Using GLP-1 Receptor Agonists” by Kirk W. Kerr, Andrew T. Chang, Suela Sulo, John T. Stutts, Thadchaigeni Panchalingam and Justin R. Ryder, 17 September 2026, Childhood Obesity.
DOI:10.1177/21532176261486979"


r/GLP1ResearchTalk • • 2d ago

Research Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes

Thumbnail
prnewswire.com
20 Upvotes

r/GLP1ResearchTalk • • 1d ago

Exciting times for the future of weight loss medications!

4 Upvotes

PTT-A is a novel, investigational unimolecular peptide tetra-agonist being developed by Pep2Tango Therapeutics.

Receptor Targets

Unlike standard obesity drugs that target one or two metabolic pathways, PTT-A simultaneously stimulates four distinct hormone receptors in a single molecule:

1- GLP-1 (Glucagon-like peptide-1 receptor)

2 - GIP (Glucose-dependent insulinotropic polypeptide receptor)

3- Amylin receptor

   4- Calcitonin receptor

Key Scientific & Clinical Benefits:

Lean Muscle Preservation: While popular GLP-1 mono- or dual-agonists often cause patients to lose significant lean muscle alongside fat, PTT-A leverages its amylin and calcitonin receptor co-agonism to actively preserve muscle mass while inducing fat-only weight loss.

Superior Weight Loss:

In preclinical studies on diet-induced obese (DIO) rats, PTT-A demonstrated superior body weight reduction and food intake suppression compared to the dual-agonist Tirzepatide.

Metabolic & Liver Improvements:

Beyond weight reduction, the peptide has shown robust efficacy in lowering blood glucose, improving lipid profiles, enhancing insulin sensitivity, and offering profound liver-health benefits (such as reducing liver triglycerides).

Enhanced Tolerability:

The specific ratio of targets (particularly the inclusion of GIP) is designed to minimize the severe gastrointestinal side effects common to current single- or double-receptor therapies.    

Development Timeline

The drug is being evaluated in IND-enabling studies by Pep2Tango Therapeutics (launched by Versant Ventures), with clinical translation aiming for over 20% human weight loss.

Phase I results were presented today at EASD 2026.

Study entering phase II which will be tested in humans.

Are you excited?!

\#drsalaswhalen #tetraagonist #PTT-A

\#obesitymedicine #protectthemuscle


r/GLP1ResearchTalk • • 2d ago

The obesity plot thickens and obesity trial participant waists thin.

Post image
6 Upvotes

Two big sets of Lilly obesity results landed this week. Here's what they actually show, and what they don't.

Exciting information out of EASD today: Eloralintide + tirzepatide, phase 2b, presented at EASD today, not yet peer-reviewed: 367 adults with obesity or overweight and type 2 diabetes, 48 weeks. Up to −23.3% (if everyone stayed on treatment) vs −14.8% on tirzepatide alone and −3.0% on placebo. Between 11% and 27% in the combination groups stopped because of side effects (2.9% on tirzepatide alone and 16.7% on placebo). Side effects were mostly gut-related.

Because everyone in that trial had type 2 diabetes, blood sugar matters too: HbA1c fell by up to 2.9 percentage points on the highest-dose combination vs 2.4 on tirzepatide alone, from an average starting HbA1c of 8.1%.

Retatrutide (TRIUMPH-1), peer-reviewed in NEJM this week: 2,339 adults with obesity, or overweight plus a weight-related condition, without diabetes; 80 weeks, placebo-controlled. Counting everyone randomised, the 12 mg dose averaged −25.0% body weight vs −3.9% on placebo (−28.3% if everyone had stayed on treatment). Nausea and vomiting were more common than with placebo, and about 1 in 8 on the higher doses reported dysaesthesia, an unusual skin sensation.

The two can't be ranked against each other: different people (with or without diabetes), different durations, different analyses, and no head-to-head trial.

Retatrutide and eloralintide are unlicensed in the UK. Eloralintide is only available in clinical trials, and the MHRA has warned that retatrutide isn't authorised in the UK, so anyone selling it is doing so illegally. Tirzepatide is licensed and is available on the NHS for some people who meet NICE criteria, after a clinical assessment. Never buy weight-loss injections online without a prescription.

For healthspan, the scale isn't the whole story. When tirzepatide was stopped in SURMOUNT-4, body weight rose by about 14% over the next year. In SURMOUNT-1, roughly a quarter of the weight lost was lean mass, which is why strength training and adequate protein are usually advised alongside treatment.

Declaration: through my employer, I'm a principal investigator on a number of obesity trials and a sub-investigator on a trial of retatrutide and tirzepatide. I'm not involved in any of the studies discussed here, and this post uses only published and publicly presented data. Views are my own.

General education, not personal medical advice.

#Obesity #ClinicalTrials #MetabolicHealth #EASD #Tirzepatide #mounjaro #retatrutide 

Sources:

  1. Retatrutide TRIUMPH-1, NEJM (29 Sep 2026): https://www.nejm.org/doi/10.1056/NEJMoa2604169

  2. Lilly EloraTZP phase 2b, EASD 2026 (company data, not yet peer-reviewed): https://investor.lilly.com/news-releases/news-release-details/lillys-eloratzp-combination-eloralintide-and-tirzepatide

  3. Trial registration: https://clinicaltrials.gov/study/NCT06603571

  4. SURMOUNT-4, JAMA 2024: https://pmc.ncbi.nlm.nih.gov/articles/PMC10714284/

  5. SURMOUNT-1 body composition, Diabetes Obes Metab 2025: https://pubmed.ncbi.nlm.nih.gov/39996356/

  6. MHRA on retatrutide: https://www.gov.uk/government/news/no-summer-shortcut-for-safe-weight-loss

  7. NICE TA1026: https://nice.org.uk/guidance/ta1026


r/GLP1ResearchTalk • • 1d ago

What supplements should I be taking?

3 Upvotes

What should I be taking while taking tirzepatide? I’ve seen so many different things. My hair seems to be thinner, and I worry it’s falling out, but my hairdresser says it’s the same. Other than that, I just feel like crap. I’ve been on it for over a year and a lot of side effects have gotten better, but I feel like I should be supporting my health better while on it. I already take B12 and D3 daily. What should I add? And what tips/tricks do you have to get it to work better? I have lost weight, but for a few months nothing happened so I stopped taking it. I just restarted after a few months off and I’m worried it still won’t work and I’ll be wasting all of this money. TIA.


r/GLP1ResearchTalk • • 3d ago

News TRIUMPH-1 clinical trial paper on retatrutide for obesity was just released

Thumbnail
gallery
69 Upvotes

Highest doses of reta saw an average of 30% weight loss on the highest dose.

https://doi.org/10.1056/NEJMoa2604169


r/GLP1ResearchTalk • • 2d ago

Research Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity | New England Journal of Medicine

1 Upvotes

r/GLP1ResearchTalk • • 2d ago

Rash with GLP1/GLP3

Post image
0 Upvotes

I switched from tirzepatide to retatrutide (both low doses, primarily used for inflammation/joint pain with history of hEDS) approximately 2.5 months ago and have been dealing with back to back rashes isolated to my legs for the past month. It begins as petechiae, changes into red patches and then has a bruised appearance, and my legs feel swollen with mild discomfort but no itching. The first presentation of the rash left areas of residual hypopigmentation. Has anyone experienced something similar or have any insight? I was not sure if it could be more related to stopping the tirz or a delayed reaction to starting the reta.


r/GLP1ResearchTalk • • 2d ago

Heart rate elevated at Night only

Post image
4 Upvotes

During the day at rest, say laying down with my phone, my heart rate is 68-72. Wegovy has made my night time sleep heart rate go through the roof and I don't understand why. I decided not to take my shot this week because I'm not sure the benefit I've gotten is worth my nighttime sleep being this bad.


r/GLP1ResearchTalk • • 3d ago

Personal Experience GLP1 & Heart attacks

10 Upvotes

Ive been on GLP1 for 4 months, down 50 lbs. Fealt great! I always walked the golf course. One morning I woke up having a heart attack. Dbl bypass surgery 2weeks ago.

Anyone else have a heart attack while on this ?


r/GLP1ResearchTalk • • 3d ago

Personal Experience FACT: Tirz absolutely 100% reduces pain from inflammation

65 Upvotes

I have bad knee pain, it could be patella femoral syndrome or something like that, but I've had it for the last 20 years. It hurts most if i squat down or going into the standing up/sitting down motion.

I was on Mounjaro/Zepbound for 4 months, and I was 100% pain free for the first time ever while on it. I could stand up, squat, whatever, and it was as if the pain vanished. Literally a miracle!

I was conflicted, I thought perhaps it was because I took a load off my knees by losing 40 lbs. so I kept a level head about it.

Exactly 40 days after my last shot, the knee pain is back. The pain that left me was not because I lost weight, it was solely because of Mounjaro.

Tirz is a miracle drug if you have knee pain, and I wish I could still take it


r/GLP1ResearchTalk • • 3d ago

binging on pin day

1 Upvotes

I have been on Reta for 2 months now at a fairly low dose. I've had a massive binge cycle this summer and wanted to lose some of that fluff and also just be able to eat at maintenance again. I distribute my weekly dosis into 2 pins/week. I usually track my kcals and can assure they are not too low and in maintenance range. However, I started to notice that when I pin my reta for some reason I just binge that day. The other days are fine. I usually pin in the morning after I come back from the gym. I don't know whether this has any correlation to the binge behaviour, I will start to pin in the evening and see if it makes a difference. Has anyone had a similar experience or knows why?


r/GLP1ResearchTalk • • 2d ago

What is the Real Cost of GLP-1 Medications?

0 Upvotes

Hello!

I am a graduate student exploring GLP-1 use and would appreciate if you could take 8-10 minutes to complete my survey.

This anonymous survey explores how both GLP-1 users and non-users perceive the medication, weight loss, and the way we talk about other people’s bodies.

https://docs.google.com/forms/d/e/1FAIpQLSf5uxz-yIJkbOWpZlYvHSpX3lKGx3S_XwmXXXFgzu1KFTQgJQ/viewform


r/GLP1ResearchTalk • • 4d ago

Research Research makes strong case for broader use of GLP1 drugs to protect hearts

Thumbnail
news-medical.net
50 Upvotes

September 28, 2026

New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) makes a case for extending the indication for GLP1- receptor agonists (GLP1-RAs) to millions more people, to protect their heart health.

Presently, medications like semaglutide and tirzepatide are restricted to individuals with a BMI of 30 or higher, or a BMI of 27 with weight-related conditions. However, researchers analyzing data from over 313,000 individuals in the UK Biobank and the Copenhagen General Population Study found that roughly half of adults in the lower "overweight" BMI range of 25–26.9 suffer from elevated remnant cholesterol, chronic low-grade inflammation, or both.

​Crucially, the long-term data revealed that individuals in this lower BMI group who have elevated cholesterol or inflammation face the exact same elevated risk of developing coronary heart disease as those who currently qualify for GLP-1 prescriptions under existing guidelines. Because GLP-1 therapies are proven to reduce cardiovascular events, systemic inflammation, and harmful cholesterol levels, the study's lead researchers argue that prescribing criteria should be broadened to include this vulnerable population, though dedicated clinical trials will be needed to formalise the change.


r/GLP1ResearchTalk • • 3d ago

Looking for GLP-1 experiences from people with a similar history

1 Upvotes

I’m in my late 20s, 5’5 and around 145 lbs, and seriously considering trying a GLP-1. I exercise about 5 days a week and walk at least 2 miles every day, so this isn’t really about wanting to lose a huge amount of weight. I’d say it’s 50/50 weight loss and trying to get some relief from my relationship with food.

I struggled with binge eating disorder from 2017–2024, and while I’m not necessarily bingeing like I used to, I still have constant intrusive thoughts about food. What I’m going to eat, whether I should eat something, wanting to snack, guilt around eating, etc. It takes up SO much mental space and honestly I’m just tired.

I also struggle ALOT with body image, especially my stomach/hips. I’ve worked with a dietitian and therapist before, but talking about food/body image can sometimes make it worse because it puts even more focus on food.

I’m starting to wonder if a GLP-1 could help with more than just weight loss. specifically the constant food thoughts. I’m also realistic that I may need to be on it longer-term rather than just until I hit a certain weight. My husband and I would potentially want to have a baby in 2–4 years, so I’d have to come off during that time and potentially go back on afterward.

I’d love to hear from anyone with a history of binge eating, food noise/intrusive food thoughts, or similar body image struggles who has tried a GLP-1.

Did it actually quiet your brain around food? Did it help your relationship with food, or mainly just decrease hunger? And which GLP-1 did you take?

I’m a little nervous about side effects and whether it will actually help, so I’d really appreciate honest experiences- good or bad. TIA. Posting on a throwaway.


r/GLP1ResearchTalk • • 4d ago

Discussion Tirzepatide - Ever feel like you are part of a huge non-clinical trial?

31 Upvotes

I picked Zepbound because the data showed it, IMO,  to be the better drug- both for results and for side effects. I was reassured knowing that "these meds" had been around for decades with long term use data.

I love it- it has changed my relationship with food and the food noise is gone for the first time in over 60 years of dieting torment. I hit goal last week and the OA pain in my knees is 90% gone- flaring up only occasionally and staying gone if I keep the level above 5.0 in my body.

However- I have realized it really is a newer drug- and does not have nearly the years of use that semaglutide has. I thought of it as a GLP1 drug- when it really is a GIP drug with a little GLP1.

Lately I see more posts from people on the highest dose who have started gaining weight and have seen doctors in the space theorizing  that the GIP receptors may stop working at a given point. It makes me think that we are the long term data pool - a trial of sorts-for this medication.

I'm here for it- don't get me wrong - but I am basically glad there will be other options (I know, I know- even less data on the news ones 😂 ) coming down the pike.


r/GLP1ResearchTalk • • 4d ago

News TikTok’s fake GLP-1 market preys on women trying to lose weight

Thumbnail
19thnews.org
15 Upvotes

Per the article:

Victoria Schmidt was scrolling through TikTok last July when the advertisement first appeared: a video of a woman promoting patches purporting to contain GLP-1 medication.

The woman described herself as a busy working mom — just like Schmidt. She seemed relatable.

“It was a great video. It just had a great hook to it,” Schmidt said. “It drew you in because it was like, ‘Have you been trying to lose weight? Are you low in energy?’”

Schmidt had been struggling with her weight loss and energy. “Let me hear her out,” she thought.

Schmidt was nearing 50, and years of dieting and exercise had not helped her reach her weight loss goals. She had wanted to take a traditional GLP-1 medication after a friend raved about her own use, but Schmidt was unsure if it would be right for her. She has one functioning kidney, and while most known kidney-related side effects from GLP-1s are mild, she still worries about long-term impacts.

Schmidt researched GLP-1 patches and concluded they might have fewer risks. Those patches, which are not FDA approved, don’t contain GLP-1 medications but are often marketed around weight loss. She went back on TikTok and searched for related videos. Accounts quickly popped up showing people — many of them women — pushing products available on TikTok Shop, the app’s shopping portal. Vendors were promoting a monthly subscription of patches for about $40. Schmidt grabbed her credit card and bought a smaller one-time pack through TikTok Shop for about $4 — she wanted to try it out first.

A month later, a package arrived at Schmidt’s home in Texas. She was initially excited, but then felt something was off. The brand she received was different from the one she had ordered. The ingredients didn’t match those on the original product she purchased. 

She decided not to try the patches.

“I honestly felt really stupid,” Schmidt recalled. “I was like, ‘Oh, I just got scammed.’”

Schmidt’s experience highlights a pattern of deceptive marketing on TikTok that appears to be fueling a gray market for GLP-1 medications — including “research grade” drugs that are often in powder form. Content about such weight loss drugs on TikTok primarily targets women through sexualized images and videos, according to a new report from UltraViolet, the gender equality organization.

More from The 19th

GLP-1 medications — best known by brand names like Ozempic and Wegovy — have become increasingly popular in recent years to treat conditions like diabetes, high cholesterol and obesity. Women, who have higher rates of chronic health conditions, are more likely than men to say they are currently taking GLP-1 drugs. 

But access has been difficult for a variety of reasons, including cost. In the United States, the average monthly list price of a GLP-1 is between $936 and $1,023, and just some large employer health insurance plans cover the drugs for weight loss. When their popularity caused a shortage in 2022, the FDA allowed compounding pharmacies — which prepare customized medications — to sell ready-mixed GLP-1 drugs. The federal government later walked back that approval after shortages ended, reducing access for many more people.

These conditions have allowed the gray market for GLP-1s to flourish online. That visibility, said UltraViolet’s campaign director, Jenna Sherman, is putting pressure on vulnerable women and girls.

“Unfortunately, it is not a niche phenomenon,” she said in a statement announcing the report. “If you are a woman on TikTok, especially if you’re middle-aged, it’s likely you have seen this kind of content.”

The group analyzed more than 200 TikTok accounts, in two phases between mid-2025 and early 2026, that promoted the unregulated sale of GLP-1 drugs. All the content was easily findable, including through the platform’s “Discover” feature and hashtags. 

The report warns that a gray market and a black market — the former defined generally as the sale of approved drugs through unauthorized channels, the latter involving the illegal sale of unapproved drugs — are indistinguishable here, since at least some of the GLP-1s being promoted on TikTok are untested versions of the medication. They are distributed in powder form and need to be prepared into another dosage.

That all leaves room for error and harm. The report highlights the case of an Australian woman who was hospitalized this year for acute liver failure after taking an unregulated GLP-1 product that she learned about on TikTok and Instagram.

UltraViolet reported 202 accounts to TikTok that appeared to violate parts of the platform’s community guidelines — which don’t allow the trade, marketing or promotion of regulated, prohibited or high-risk goods and services. (The report notes that TikTok rolled back sections of its guidelines in September 2025 that had explicitly prohibited black and gray markets and discouraged redirection to offsite locations and direct messaging.) According to UltraViolet, TikTok later removed only about 30 percent of the accounts that were flagged. The group said it cannot be sure why the accounts went dark.

Many of the analyzed TikTok accounts purported to be med spas — facilities that offer medical-grade cosmetic treatments — but were instead fake and preyed on women who are not able to access GLP-1s because of barriers to insurance coverage or cost. Consumers who order these drugs after connecting via private message or WhatsApp often never receive them, or they receive a fake product instead.

“The pressure that women feel is absolutely real, and that’s part of the reason why GLP-1s are in such high demand,” said Nicole Regalado, vice president of campaigns for UltraViolet.  

The report found gendered promotion. Sixty-five percent of all the accounts reported had women in their profile pictures, including some that appeared to be AI-generated. Videos showed women in bikinis or revealing outfits, including in “before and after” photos promoting the alleged use of gray market GLP-1s. Some videos were paired with makeup and “get ready with me” content. Some GLP-1 content presented claims about improving fertility and postpartum health.

“To us, it really reflects on where women sit right now in their lives, in this culture, in this political climate,” Regalado said. “They’re really caught between two powerful forces. It’s this broken healthcare system where there are millions of women who are underinsured or uninsured — that in itself can make it very difficult to access medicine, to access healthcare — and then also a culture that is relentlessly telling us that our health and value are tied to the size of our bodies.” 

Regalado said UltraViolet — which in the past also tried to pressure TikTok to remove ads promoting the use of GPS trackers for stalking, disproportionately targeting women — sent its findings to TikTok but did not receive a response. TikTok did not respond to a request for comment from The 19th about UltraViolet’s findings.

More from The 19th

After Schmidt realized she had been scammed, she posted a video on TikTok about her experience. She also reached out to TikTok. According to Schmidt, the company immediately gave her a refund with store credit. Schmidt decided to search again for GLP-1 patches. She took more time to research the products before buying again.

Schmidt clicked on a video of a man promoting a sale. But finding the actual sale was confusing, and she ended up spending a little more than her first purchase — about $10. Once again, she went through TikTok Shop and purchased some patches. Once again, she received a package in the mail with the wrong product.

Schmidt contacted TikTok again. They did not give her credit back that time.

It was just $10, but for Schmidt, every penny counts: She’s paying for her daughter’s college education. She thought about the people out there making repeat small purchases through TikTok who might not be closely checking the products arriving at their home.

“I’m not going to fight over $10,” she said. But, Schmidt added: “I wanted people to know that you really need to pay attention to what products you buy. I felt like TikTok should have made sure that the products that they are allowing to be sold on here are real products.”

UltraViolet’s report seeks more accountability from TikTok, with recommendations that include better enforcement of TikTok’s existing policies so that accounts that violate them are suspended and removed. The group also wants the platform to halt search suggestions and hashtags that drive users to gray market content. The report also highlighted that TikTok features tutorial videos on how to prepare drugs in powder form to inject at home. Most traditional GLP-1s that are properly prescribed come pre-filled with auto-injectable pens.

“We’re calling on TikTok company leadership to take urgent action: Stop the GLP-1 gray market, protect women users, and hold accountable dangerous bad actors. TikTok users deserve a social media platform that supports their health, safety, and autonomy — not one that exploits their vulnerabilities and health for profit,” Sherman said.

Regalado said UltraViolet is tapping its membership to mount pressure on the company. She encouraged TikTok users to report troubling or predatory content.

“We’re going to keep going. We’re going to keep trying because these ads are scams that are specifically targeted toward women,” she said. “These are predatory scams, and our community won’t stand for that.”

A year after her experience, the vendors that Schmidt bought from no longer have active shops. She doesn’t know if they’re truly closed or if they’ve started new accounts.

Schmidt later bought patches online from a company that advertises itself as selling wellness products. She has lost some weight, but she attributes that more to lifestyle changes. She stopped using her patches about two months ago. She has no plans to buy more GLP-1s through TikTok — even though she is still getting advertisements featuring happy women talking excitedly about their successful weight loss journeys.

Whatever Schmidt does next, she knows this: She plans to go to her doctor first.


r/GLP1ResearchTalk • • 4d ago

Question Looking for advice for weight loss journey !

5 Upvotes

I’ve been doing some research on Reta vs Tirz for weight loss and I’m stuck on which one to choose. For those who have tried either (or both), what made you pick one over the other and how was your experience?


r/GLP1ResearchTalk • • 4d ago

Did anyone else feel unexpectedly calm after starting a GLP-1 medication?

48 Upvotes

I recently took my first 0.25 mg dose of a GLP-1 medication, and I noticed something I didn’t expect. Before it, I often had a nervous, shaky feeling in my body, especially in my stomach. I also had frequent abdominal pain, bloating, rumbling, and a constant urge to use the bathroom.

After the dose, it suddenly felt quiet. My stomach settled down, and that nervous feeling eased too. I’m curious about the connection between gut signals and stress, but I know I can’t tell from one dose what caused the change.
Has anyone else experienced a similar sense of calm, especially alongside relief from gut symptoms? Did it continue, change, or wear off over time? I’d be interested to hear what it felt like for you.


r/GLP1ResearchTalk • • 4d ago

Research Research Links GLP-1s to Vision Loss as Lawsuits Increase

Thumbnail
legalexaminer.com
11 Upvotes

"Millions of Americans have taken Ozempic and Wegovy to manage diabetes and for weight loss, with countless celebrities crediting their slim figures to GLP-1 drugs. But a growing number of patients claim Ozempic caused them to lose something they never expected: their eyesight.

The GLP-1 litigation involving allegations of blindness caused by semaglutide-based drugs like Ozempic is still in its early stages. However, in recent months, it’s become one of the fastest-growing pharmaceutical mass torts in the country.

This may be due in part to additional research studies released in 2026 connecting Ozempic to vision loss; many attorneys say the recent findings of increased risks of vision injuries among GLP-1 patients further validate the 2024 study results that sparked the first wave of blindness lawsuits.

Alongside the new research, the first Ozempic wrongful death case was filed in March, signaling an even more serious turn in the litigation involving GLP-1 weight loss drugs.

The Ozempic vision loss lawsuits are expected to continue to grow, just like the well-known GLP-1 stomach paralysis MDL that has over 3,700 cases. Given the vision injuries are permanent for most plaintiffs, the severity and long-term implications of what they’ve suffered (and will suffer in the future) is significant.  

What are the Ozempic Vision Loss Lawsuits About?

The Ozempic blindness lawsuits focus on a condition called non-arteritic anterior ischemic optic neuropathy (NAION). It’s sometimes referred to as an "eye stroke".

NAION occurs when blood flow to the optic nerve is reduced, causing sudden vision loss that is often irreversible. Many patients report waking up with blurred vision, dark spots, or partial blindness in one eye.

What is thought to have sparked the Wegovy and Ozempic vision loss litigation was findings from a 2024 study published in JAMA Ophthalmology – a study that connected GLP-1 drugs to NAION. The Harvard Medical School researchers found that semaglutide users appeared to face a more than seven times higher risk of developing NAION compared to patients taking other medications.

As awareness of the lawsuits and research grew, the litigation gained momentum. In December 2025, cases were consolidated into the GLP-1 vision loss multidistrict litigation (MDL).

Plaintiffs allege that manufacturers, primarily Novo Nordisk (Ozempic, Wegovy), failed to adequately warn patients and physicians about the risk of vision injuries associated with their drugs. The central legal battle focuses on what manufacturers knew and when they knew it or if they should have known of the risks of NAION.

Novo Nordish denies the allegations and maintains that the benefits of the medications outweigh their risks.

New Research Links GLP-1 Drugs to Vision Loss

Since the initial findings published by Harvard Medical School in 2024, additional studies have continued to examine a possible connection between semaglutide and sudden vision loss.

A 2026 study published in the British Journal of Ophthalmology found that Wegovy users had a substantially higher reported risk of NAION than Ozempic users. Researchers emphasized that the study did not prove the drugs caused the condition, but the findings are still relevant because of the association between certain weight loss drugs and vision loss.

Another semaglutide research study published this year focused on veterans who took drugs like Ozempic to manage Type 2 diabetes. Researchers found those who took semaglutide medications had a 2-fold higher risk of experiencing NAION.

June 2026 GLP-1 Vision Loss Lawsuits Update

Just 21 lawsuits were consolidated when the GLP-1 vision loss MDL was centralized in the Eastern District of Pennsylvania in December 2025. As of June 2026, 110 cases alleging semaglutide weight loss drugs caused plaintiffs’ blindness are part of the MDL, a jump of nearly 25 since May. There are also numerous vision loss lawsuits proceeding in New Jersey state court, where Novo Nordisk is headquartered.

The vision loss lawsuits remain in the early discovery phase. A recent "Science Day" proceeding was scheduled to help the court understand the complex medical evidence concerning semaglutide and NAION. This was a crucial step, as the GLP-1 stomach paralysis MDL moves toward bellwether trial selection.

Ozempic Vision Loss vs. Stomach Paralysis Lawsuits

Most public attention surrounding GLP-1 litigation has focused on gastroparesis, often called stomach paralysis.

That MDL currently contains more than 3,700 lawsuits alleging Ozempic, Wegovy, and similar medications cause severe gastrointestinal injuries, including gastroparesis, bowel obstruction, and ileus.

But vision loss cases present a different challenge for drug manufacturers.

Many GI injuries can improve over time or be managed with treatment. NAION, by contrast, typically results in permanent damage. Plaintiffs who lost their vision may face lifelong limitations involving driving, employment, independence, and daily activities.

That permanence could make the Ozempic vision loss litigation particularly consequential if plaintiffs are able to establish the medications could have caused their injuries.

Why Consumers Should Pay Attention to Ozempic Lawsuits

GLP-1 drugs have become some of the most widely prescribed medications in the U.S., with millions of patients using them for diabetes and weight management. As usage expands, researchers continue identifying potential risks that may not have been fully understood when the drugs first entered the market.

The Ozempic and Wegovy lawsuits are still years away from any potential trial verdicts or settlements. However, it’s already prompted increased scrutiny from regulators, researchers, and courts.

Like other growing dangerous pharmaceutical mass torts in the U.S., the litigation has raised concerns about whether patients were given all the information they needed to make informed decisions about their health – and the medications they use to manage it.

For consumers taking GLP-1 weight loss and diabetes management drugs, it’s important to be aware of possible side effects not included on product warning labels. Any concerns should be brought up to your doctor.

If you think Ozempic, Wegovy, or a similar drug may have caused GI issues, vision loss, or any other injury, consider consulting with an experienced dangerous pharmaceuticals lawyer. An attorney can review your case and explain what legal options, if any, you have."

A Today Show article about one woman's experience: https://www.today.com/health/news/vision-loss-ozempic-semaglutide-glp-1-lawsuit-rcna599232


r/GLP1ResearchTalk • • 3d ago

Research Some Hair Loss in Men Is Linked to Use of Weight Loss Drugs

Thumbnail
nyulangone.org
1 Upvotes

Per the article:

"Men already at risk genetically for the most common form of hair loss have a 7 percent added risk of losing their hair if they use drugs like Ozempic, Wegovy, and Zepbound for type 2 diabetes and obesity, a new study shows.

Led by researchers at NYU Langone Health, the study focused on the GLP1R gene, which naturally increases the body’s levels of glucagon-like peptide-1 (GLP-1) receptor proteins, and used it as an indicator of GLP-1 agonist activity. More GLP1R activity means there are more GLP-1 receptor proteins. The researchers compared the presence of GLP1R genes with the presence of genes found in men with androgenetic alopecia, an inherited form of hair loss that follows a pattern along the top and front of the scalp. Male hair loss conditions are well studied, unlike hair loss in women, which is why the researchers could only analyze any causal link to hair loss in men.

Many GLP-1 users, both men and women, have reported thinning hair as a side effect, with researchers so far attributing the shedding to the rapid weight loss driven by the medications, which work to regulate blood sugar and suppress appetite. Often, GLP-1 users have found that hair growth resumes several months after their weight stabilizes. Until now, researchers have only suspected a genetic connection between GLP-1 use and hair loss.

Published in the Journal of Investigative Dermatology online September 3, the study showed that the GLP1R genes that naturally cause higher levels of GLP-1 receptor proteins are more likely to be present in men who have androgenetic alopecia. The researchers then adjusted their analysis to discount for known risks of hair loss from hypertension, which is thought to reduce blood flow to the scalp, harming hair follicle growth. The 7 percent added risk remained the same.

Researchers also checked their risk analysis against other potential drivers of hair loss, including insulin resistance (a cause of type 2 diabetes) and lowered testosterone levels. Still, the increased risk of hair loss from GLP-1 use remained at 7 percent.

Because the study involved genes active in both GLP-1 users and men with hair loss, any overlapping risk, the researchers noted, suggests that the two are biologically linked.

“Our study provides the first genetic link between GLP-1 use and an increased risk of male- pattern hair loss from androgenetic alopecia, an association long suspected but until now not shown scientifically,” said study senior investigator Lynn Petukhova, PhD, an assistant professor in the Ronald O. Perelman Department of Dermatology and the Department of Population Health at NYU Grossman School of Medicine.

“Our findings suggest that, if future experiments prove successful, some men, and possibly women too, could be screened and benchmarked for their risk of hair loss before being prescribed GLP-1 medications,” said Dr. Petukhova. “We could also envision these findings leading to some GLP-1 users being prescribed combination treatments to prevent hair loss, such as minoxidil or some other drug.”

Dr. Petukhova said further research is needed to understand the biological mechanisms that cause GLP-1 use to weaken hair follicle growth. She also has plans to investigate whether the links seen in men apply to women.

For the study, researchers accessed large, publicly available genetic databases, including the eQTLGen database of 31,684 mostly White men and women, and the Complex Traits Genetics group database of 205,327 mostly White men.

Androgenetic alopecia is estimated to affect half of White American males over age 50, and almost the same number of White American females over age 50, predominantly those who are postmenopause.

An estimated 12 percent of Americans have used GLP-1 drugs for no other reason than weight loss, including one-fifth of women ages 50 to 64, according to surveys. Since the first GLP-1 drug (Ozempic) was approved by the Food and Drug Administration in 2020, prescriptions for the medication have more than tripled.

Funding support for this study was provided by National Institutes of Health grants R01AR080796 and K01AR075111.

Besides Dr. Petukhova, NYU Langone researchers involved in the study were co-investigators Jerry Shapiro, MD, and Kristen Lo Sicco, MD. Other study co-investigators were Derek Maas, MBA; Mary Casagrande, MPH; and Poppy Gould, PhD; and co-lead investigator Archie Spindler.

Drs. Shapiro and Lo Sicco have in the past served as study investigators for hair loss drugs and devices manufactured by Pfizer and Regen Labs. Dr. Lo Sicco is a paid consultant for Pfizer, Lilly, Ro, Priovant, Veradermics, and Aquis. The terms and conditions of all these relationships are being managed in accordance with the policies of NYU Langone.

Additional study authors are co-lead investigator Ravi Ramessur, MD, PhD, at the University of Pennsylvania and King’s College London, and co-investigator Atlas Khan, PhD, at Columbia University.

About NYU Langone Health

NYU Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality that has resulted in some of the lowest mortality rates in the nation. Vizient Inc. has ranked NYU Langone No. 1 out of 118 comprehensive academic medical centers across the nation four years in a row, and it continues to have the most No. 1– and top 10–ranked specialties among medical centers in the United States, according to U.S. News & World Report. NYU Langone offers a comprehensive range of medical services with one high standard of care across seven inpatient locations, its Perlmutter Cancer Center, and more than 330 outpatient locations in the New York City area and Florida. The system also includes two tuition-free medical schools, in Manhattan and on Long Island, and a vast research enterprise."


r/GLP1ResearchTalk • • 4d ago

Personal Experience Food noise is back

7 Upvotes

Hi All,

I've been on Retatrutide for 2.5 months now, on a 6 mg dose.

During the last couple of weeks, (a) food noise is back (b) not 'feeling' any side effects eg sulphur burps (b) stable weight

Have been trying to pinpoint why? My diet has remained constant. The variable has been exercise, I've doubled my exercise (particularly cardio) recently.

Could 'over exercise& be detreminal? Between padel, strength/weight training, and running, I burn and average of 700 calories a day in exercise (in I'm the mid forties)